BRISBANE, Calif., Oct. 21, 2008 (GLOBE NEWSWIRE) -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing PARP inhibitors as novel cancer therapies, announced today that John Schembri, BiPar's vice president and chief financial officer, will present information on BiPar's development programs and product pipeline, including the company's lead product candidate, BSI-201 which is in Phase 2 clinical trials, at the 2008 BIO Investor Forum in San Francisco, CA. Mr. Schembri will present on October 30, 2008, at 8:30 a.m. PT at the Palace Hotel located at 2 New Montgomery Street, San Francisco.
About BiPar Sciences and BSI-201
BiPar Sciences, Inc. is a clinical-stage biopharmaceutical company developing and commercializing a novel class of tumor-selective drugs designed to address unmet needs of cancer patients. The company's lead product candidate is BSI-201, which is in Phase 2 testing for triple negative breast cancer, ovarian cancer and other malignancies. BSI-201 is a poly (ADP-ribose) polymerase (PARP) inhibitor, a targeted approach to treating solid tumors by preventing cancer cells from repairing damaged DNA, ultimately causing the cancer cells to die. The company is also conducting preclinical studies on two additional compounds, BSI-401 (PARP inhibitor) and BSI-302 (anti-tubulin program). BiPar Sciences is privately held with headquarters in Brisbane, California. For more information, please visit www.biparsciences.com.